Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

MS Trust critical of guidance on multiple sclerosis.
MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.
Interferon-β Modulates Inflammatory Response in Cerebral Ischemia.
Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes.
Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy.
17β-estradiol enhances the efficacy of adipose-derived mesenchymal stem cells on remyelination in mouse model of multiple sclerosis.
Evidence of aquaporin involvement in human central pontine myelinolysis.
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
What lies beneath grey matter atrophy in multiple sclerosis?
Towards a predictive model for Guillain-Barré syndrome.
Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelization attacks.
Immunosuppressive potential of human amnion epithelial cells in the treatment of experimental autoimmune encephalomyelitis.
Advances in the management of multiple sclerosis spasticity: recent clinical trials.
Possible role of human herpesvirus 6 as a trigger of autoimmune disease.
A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.
Remyelination therapy goes to trial for multiple sclerosis.
CD24 gene allele variation is not associated with oligoclonal IgG bands and IgG index of multiple sclerosis patients.
Diffusion tensor imaging of the trigeminal nerve in patients with trigeminal neuralgia due to multiple sclerosis.
Systematic imaging review: Multiple Sclerosis.
VZV encephalitis that developed in an immunized patient during fingolimod therapy.
Enlargement of cerebral ventricles as an early indicator of encephalomyelitis.
Proteomic analysis for early neurodegenerative biomarker detection in an animal model.
No evidence of human herpesvirus DNA in the CSF of multiple sclerosis patients.
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
Conclusion: National incidence and risk factor assessments may become a basis for the evaluation of prevention trials - prospects from the Third Nordic MS Symposium.

Pages